review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Odelia Cooper | Q42659703 |
P2093 | author name string | Anat Ben-Shlomo | |
P2860 | cites work | Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain | Q28119149 |
Mechanisms for pituitary tumorigenesis: the plastic pituitary | Q33630319 | ||
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors | Q33680681 | ||
Genomic characterization of human and rat prolactinomas | Q34277575 | ||
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice | Q34745279 | ||
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. | Q34942996 | ||
Recurrent gain-of-function USP8 mutations in Cushing's disease | Q35146226 | ||
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas | Q35578652 | ||
The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease | Q35813265 | ||
Review on EGFR Inhibitors: Critical Updates | Q35964161 | ||
Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas | Q36231629 | ||
Expression and function of ErbB receptors and ligands in the pituitary | Q37135031 | ||
Heregulin regulates prolactinoma gene expression | Q37208143 | ||
Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Adrenocorticotropic Hormone Production and Tumorous Corticotroph Cell Growth in AtT20 Cells | Q37228518 | ||
Mutations in the deubiquitinase gene USP8 cause Cushing's disease | Q41716700 | ||
UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation | Q42833376 | ||
Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes | Q43148533 | ||
14-3-3-dependent inhibition of the deubiquitinating activity of UBPY and its cancellation in the M phase. | Q53532387 | ||
Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues | Q74453740 | ||
The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease | Q86717911 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 301-305 | |
P577 | publication date | 2017-05-17 | |
P1433 | published in | Current Opinion in Endocrinology, Diabetes and Obesity | Q15756285 |
P1476 | title | Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside | |
P478 | volume | 24 |
Q99545483 | Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor |
Q60921593 | Biomarker Discovery for Immunotherapy of Pituitary Adenomas: Enhanced Robustness and Prediction Ability by Modern Computational Tools |
Q90139182 | Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough? |
Q90111954 | Dopamine agonist resistant prolactinomas: any alternative medical treatment? |
Q92210576 | Emerging and Novel Treatments for Pituitary Tumors |
Q93063035 | Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies |
Q49330862 | Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). |
Q55249109 | New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A. |
Q47168700 | Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas |
Search more.